MYCi361

Overview

MYCi361 (NUCC-0196361) is a MYC inhibitor with the K d of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy.

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > c-Myc

Product Information

• Catalog No.: HY-129600
• CAS No.: 2289690-31-7
• Molecular Formula: C26H16ClF9N2O2
• Molecular Weight: 594.86
• Purity: 99.95%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (3.50 mM); Clear solution
• Availability: In-stock

Source

Original product source